gpt-dict.com

SAMe for Liver Health

Verdict: Weak, mostly negative evidence for liver health

For general liver health, taking a SAMe supplement is not well supported: the highest-quality trials show it works no better than placebo, and any signal of benefit comes from prescription ademetionine in specific cholestasis settings rather than over-the-counter supplements. If you have liver disease, treat it as unproven and see a doctor rather than self-medicating.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is Weak (C) because the strongest evidence is negative. A 2006 Cochrane systematic review (PMID 16625556) found no significant effect of SAMe on mortality or any liver outcome in alcoholic liver disease and advised against using it outside trials, and a 2011 double-blind RCT (PMID 22044287, n=37, 24 weeks) found SAMe no better than placebo, with the improvements seen attributed to alcohol abstinence rather than the supplement.

Where benefit appears, it is narrow and surrogate-level. A 2015 meta-analysis of chronic liver disease (PMID 25774783, 11 RCTs, n=705) lowered bilirubin and AST but not ALT, and comparators UDCA and SNMC outperformed SAMe. In intrahepatic cholestasis a 2020 review (PMID 32184941) reported faster ALT drops with prescription ademetionine, but it carried a manufacturer (Abbott) conflict of interest; for cholestasis of pregnancy a 2014 meta-analysis (PMID 25173231) found UDCA superior, making SAMe at best second-line.

Regulators and clinics reinforce the caution. The US FDA/NCCIH note SAMe is only a dietary supplement in the US while it is a prescription drug (ademetionine) in parts of Europe, so a retail supplement should not borrow the drug's indications. Mayo Clinic states more studies are needed before SAMe can be called beneficial for liver disease, and no major US liver society endorses the supplement. Bottom line: marginal surrogate-marker data, negative clinical-outcome data, and no authoritative backing.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
75%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.29
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L11 AI re-checkIndependent read
0.50
L1 ExamineGlobal benchmark
0.70
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.441
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

S-adenosyl-L-methionine for alcoholic liver diseases (Cochrane systematic review)
PMID: 16625556 2006 Cochrane SR n = 0
Finding: The Cochrane review could not demonstrate any significant clinical effect of SAMe on the course of alcoholic liver disease; only one trial reported mortality and the result was not significant. Authors concluded SAMe should not be used for alcoholic liver disease outside randomized clinical trials.
🟢 High quality Academic Effect size: No significant effect on mortality or liver-related outcomes
View on PubMed
S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial
PMID: 22044287 2011 隨機對照試驗 n = 37
Finding: After 24 weeks, AST, ALT and bilirubin improved in the whole cohort, but there were no differences between SAMe and placebo in any clinical, biochemical or histological parameter. Improvements were attributed to alcohol abstinence rather than SAMe.
Government Effect size: No between-group difference; SAMe no more effective than placebo
View on PubMed
S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis
PMID: 25774783 2015 統合分析 n = 705
Finding: Across 11 RCTs (705 patients, seven types of chronic liver disease) SAMe significantly reduced TBIL and AST (AST MD -16.15, p=0.0003) but did not significantly improve ALT. Comparators UDCA and SNMC showed superior efficacy for certain conditions; safety was comparable to placebo.
Government Effect size: AST MD -16.15 (p=0.0003); ALT NS
View on PubMed
Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review
PMID: 32184941 2020 系統性回顧 n = 1,791
Finding: Across 9 trials (3 randomized, 6 non-randomized; 1791 patients) both placebo-controlled RCTs reported significant ALT reductions with ademetionine vs placebo within 2 weeks, with continued improvement through 8 weeks. One author was employed by Abbott, the manufacturer of the AdoMet product, raising a conflict-of-interest concern.
🟠 Limited quality ⚠️ Industry-funded Effect size: Significant ALT reduction within 2 weeks (RCT subset)
View on PubMed
Meta-analysis of ursodeoxycholic acid and S-adenosylmethionine for improving the outcomes of intrahepatic cholestasis of pregnancy
PMID: 25173231 2014 統合分析 n = 0
Finding: Meta-analysis of RCTs comparing UDCA, SAMe and combination therapy for intrahepatic cholestasis of pregnancy found UDCA more effective than SAMe on several outcomes; combination therapy offered some additional benefit. UDCA is the preferred first-line agent for ICP.
Effect size: UDCA superior to SAMe on key ICP outcomes
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
A lab-made form of SAMe is sold as a dietary supplement in the U.S., but SAMe has been sold as a prescription drug in parts of Europe for decades. source↗
L4d TW TFDA / 衛福部
Neutral
從 1970 年代起，歐洲已廣泛使用 SAMe 來治療憂鬱症及其他生理狀況；1999 年美國則依《膳食補充劑健康與教育法》核准口服腸溶 SAMe 劑型，使消費者得於零售通路購買。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
More studies are needed to determine whether SAMe is beneficial for people who have liver disease. source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Against
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-s-adenosylmethionine-001 繁體中文版 →